APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dry Age-Related Macular Degeneration

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dry Age-Related Macular Degeneration Market Outlook and Growth Opportunities 2026

Report ID 173986680430 December 2025190 pages

Choose your research edition.

Industry ResearchDry Age-Related Macular Degeneration Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Dry Age-Related Macular Degeneration Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Dry Age-Related Macular Degeneration Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dry Age-Related Macular Degeneration Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Dry Age-Related Macular Degeneration Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Dry Age-Related Macular Degeneration market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dry Age-Related Macular Degeneration is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dry Age-Related Macular Degeneration market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dry Age-Related Macular Degeneration market include Santen Pharmaceuticals, Y2 Solution, Stealth Biotherapeutics, Phio Pharmaceuticals, Ocumension Therapeutics, Kubota Vision, Iveric Bio, Eyestem Research and Belite Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Dry Age-Related Macular Degeneration market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dry Age-Related Macular Degeneration and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dry Age-Related Macular Degeneration revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Dry Age-Related Macular Degeneration market.

Dry Age-Related Macular Degeneration Segment by Company

Santen Pharmaceuticals

Y2 Solution

Stealth Biotherapeutics

Phio Pharmaceuticals

Ocumension Therapeutics

Kubota Vision

Iveric Bio

Eyestem Research

Belite Bio

Bausch Health

Allergan

Alimera Science

Dry Age-Related Macular Degeneration Segment by Type

Oral

Injectables

Dry Age-Related Macular Degeneration Segment by Application

Above 40 Years

Above 60 Years

Above 75 Years

Dry Age-Related Macular Degeneration Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Dry Age-Related Macular Degeneration status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Dry Age-Related Macular Degeneration key companies, revenue, market share, and recent developments.

3. To split the Dry Age-Related Macular Degeneration breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Dry Age-Related Macular Degeneration market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dry Age-Related Macular Degeneration significant trends, drivers, influence factors in global and regions.

6. To analyze Dry Age-Related Macular Degeneration competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Age-Related Macular Degeneration market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dry Age-Related Macular Degeneration and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Age-Related Macular Degeneration.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dry Age-Related Macular Degeneration industry.

Chapter 3: Detailed analysis of Dry Age-Related Macular Degeneration company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Dry Age-Related Macular Degeneration in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Dry Age-Related Macular Degeneration in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dry Age-Related Macular Degeneration Industry Trends Table 2. Dry Age-Related Macular Degeneration Industry Drivers Table 3. Dry Age-Related Macular Degeneration Industry Opportunities and Challenges Table 4. Dry Age-Related Macular Degeneration Industry Restraints Table 5. Global Dry Age-Related Macular Degeneration Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dry Age-Related Macular Degeneration Revenue Share by Company (2021-2026) Table 7. Global Dry Age-Related Macular Degeneration Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Dry Age-Related Macular Degeneration Key Company Manufacturing Base & Headquarters Table 9. Global Dry Age-Related Macular Degeneration Company, Product Type & Application Table 10. Global Dry Age-Related Macular Degeneration Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Dry Age-Related Macular Degeneration by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injectables Table 16. Global Dry Age-Related Macular Degeneration Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Dry Age-Related Macular Degeneration Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Dry Age-Related Macular Degeneration Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Dry Age-Related Macular Degeneration Sales Value Share by Type (2021-2026) Table 20. Global Dry Age-Related Macular Degeneration Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Above 40 Years Table 22. Significant Companies of Above 60 Years Table 23. Significant Companies of Above 75 Years Table 24. Global Dry Age-Related Macular Degeneration Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Dry Age-Related Macular Degeneration Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Dry Age-Related Macular Degeneration Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Dry Age-Related Macular Degeneration Sales Value Share by Application (2021-2026) Table 28. Global Dry Age-Related Macular Degeneration Sales Value Share by Application (2027-2032) Table 29. Global Dry Age-Related Macular Degeneration Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Dry Age-Related Macular Degeneration Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Dry Age-Related Macular Degeneration Sales Value Share by Region (2021-2026) Table 32. Global Dry Age-Related Macular Degeneration Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Dry Age-Related Macular Degeneration Sales Value Share by Region (2027-2032) Table 34. Global Dry Age-Related Macular Degeneration Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Dry Age-Related Macular Degeneration Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Dry Age-Related Macular Degeneration Sales Value Market Share by Country (2021-2026) Table 37. Global Dry Age-Related Macular Degeneration Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Dry Age-Related Macular Degeneration Sales Value Market Share by Country (2027-2032) Table 39. Santen Pharmaceuticals Company Information Table 40. Santen Pharmaceuticals Business Overview Table 41. Santen Pharmaceuticals Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio Table 43. Santen Pharmaceuticals Recent Development Table 44. Y2 Solution Company Information Table 45. Y2 Solution Business Overview Table 46. Y2 Solution Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Y2 Solution Dry Age-Related Macular Degeneration Product Portfolio Table 48. Y2 Solution Recent Development Table 49. Stealth Biotherapeutics Company Information Table 50. Stealth Biotherapeutics Business Overview Table 51. Stealth Biotherapeutics Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product Portfolio Table 53. Stealth Biotherapeutics Recent Development Table 54. Phio Pharmaceuticals Company Information Table 55. Phio Pharmaceuticals Business Overview Table 56. Phio Pharmaceuticals Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio Table 58. Phio Pharmaceuticals Recent Development Table 59. Ocumension Therapeutics Company Information Table 60. Ocumension Therapeutics Business Overview Table 61. Ocumension Therapeutics Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Ocumension Therapeutics Dry Age-Related Macular Degeneration Product Portfolio Table 63. Ocumension Therapeutics Recent Development Table 64. Kubota Vision Company Information Table 65. Kubota Vision Business Overview Table 66. Kubota Vision Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Kubota Vision Dry Age-Related Macular Degeneration Product Portfolio Table 68. Kubota Vision Recent Development Table 69. Iveric Bio Company Information Table 70. Iveric Bio Business Overview Table 71. Iveric Bio Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Iveric Bio Dry Age-Related Macular Degeneration Product Portfolio Table 73. Iveric Bio Recent Development Table 74. Eyestem Research Company Information Table 75. Eyestem Research Business Overview Table 76. Eyestem Research Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eyestem Research Dry Age-Related Macular Degeneration Product Portfolio Table 78. Eyestem Research Recent Development Table 79. Belite Bio Company Information Table 80. Belite Bio Business Overview Table 81. Belite Bio Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Belite Bio Dry Age-Related Macular Degeneration Product Portfolio Table 83. Belite Bio Recent Development Table 84. Bausch Health Company Information Table 85. Bausch Health Business Overview Table 86. Bausch Health Dry Age-Related Macular Degeneration Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bausch Health Dry Age-Related Macular Degeneration Product Portfolio Table 88. Bausch Health Recent Development Table 89. Allergan Company Information Table 90. Allergan Business Overview Table 91. Allergan Dry Age-Related Macular Degeneration Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Allergan Dry Age-Related Macular Degeneration Product Portfolio Table 93. Allergan Recent Development Table 94. Alimera Science Company Information Table 95. Alimera Science Business Overview Table 96. Alimera Science Dry Age-Related Macular Degeneration Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Alimera Science Dry Age-Related Macular Degeneration Product Portfolio Table 98. Alimera Science Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Dry Age-Related Macular Degeneration Product Image Figure 2. Global Dry Age-Related Macular Degeneration Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dry Age-Related Macular Degeneration Market Size (2021-2032) & (US$ Million) Figure 4. Global Dry Age-Related Macular Degeneration Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injectables Image Figure 9. Global Dry Age-Related Macular Degeneration Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Dry Age-Related Macular Degeneration Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Dry Age-Related Macular Degeneration Sales Value Share by Type (2021-2032) Figure 12. Above 40 Years Image Figure 13. Above 60 Years Image Figure 14. Above 75 Years Image Figure 15. Global Dry Age-Related Macular Degeneration Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Dry Age-Related Macular Degeneration Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Dry Age-Related Macular Degeneration Sales Value Share by Application (2021-2032) Figure 18. Global Dry Age-Related Macular Degeneration Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Dry Age-Related Macular Degeneration Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Dry Age-Related Macular Degeneration Sales Value (2021-2032) & (US$ Million) Figure 21. North America Dry Age-Related Macular Degeneration Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Dry Age-Related Macular Degeneration Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Dry Age-Related Macular Degeneration Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Dry Age-Related Macular Degeneration Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Dry Age-Related Macular Degeneration Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Dry Age-Related Macular Degeneration Sales Value (2021-2032) & (US$ Million) Figure 27. South America Dry Age-Related Macular Degeneration Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Dry Age-Related Macular Degeneration Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Dry Age-Related Macular Degeneration Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injectables
Applications
  • Above 40 Years
  • Above 60 Years
  • Above 75 Years
Companies covered
  • Santen Pharmaceuticals
  • Y2 Solution
  • Stealth Biotherapeutics
  • Phio Pharmaceuticals
  • Ocumension Therapeutics
  • Kubota Vision
  • Iveric Bio
  • Eyestem Research
  • Belite Bio
  • Bausch Health
  • Allergan
  • Alimera Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dry Age-Related Macular Degeneration Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dry Age-Related Macular Degeneration Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Dry Age-Related Macular Degeneration Market Dynamics
  1. 2.1 Dry Age-Related Macular Degeneration Industry Trends
  2. 2.2 Dry Age-Related Macular Degeneration Industry Drivers
  3. 2.3 Dry Age-Related Macular Degeneration Industry Opportunities and Challenges
  4. 2.4 Dry Age-Related Macular Degeneration Industry Restraints
3 Dry Age-Related Macular Degeneration Market by Company
  1. 3.1 Global Dry Age-Related Macular Degeneration Company Revenue Ranking in 2025
  2. 3.2 Global Dry Age-Related Macular Degeneration Revenue by Company (2021-2026)
  3. 3.3 Global Dry Age-Related Macular Degeneration Company Ranking (2024-2026)
  4. 3.4 Global Dry Age-Related Macular Degeneration Company Manufacturing Base and Headquarters
  5. 3.5 Global Dry Age-Related Macular Degeneration Company Product Type and Application
  6. 3.6 Global Dry Age-Related Macular Degeneration Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Dry Age-Related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Dry Age-Related Macular Degeneration Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Dry Age-Related Macular Degeneration Market by Type
  1. 4.1 Dry Age-Related Macular Degeneration Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injectables
  4. 4.2 Global Dry Age-Related Macular Degeneration Sales Value by Type
  5. 4.2.1 Global Dry Age-Related Macular Degeneration Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Dry Age-Related Macular Degeneration Sales Value by Type (2021-2032)
  7. 4.2.3 Global Dry Age-Related Macular Degeneration Sales Value Share by Type (2021-2032)
5 Dry Age-Related Macular Degeneration Market by Application
  1. 5.1 Dry Age-Related Macular Degeneration Application Introduction
  2. 5.1.1 Above 40 Years
  3. 5.1.2 Above 60 Years
  4. 5.1.3 Above 75 Years
  5. 5.2 Global Dry Age-Related Macular Degeneration Sales Value by Application
  6. 5.2.1 Global Dry Age-Related Macular Degeneration Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dry Age-Related Macular Degeneration Sales Value by Application (2021-2032)
  8. 5.2.3 Global Dry Age-Related Macular Degeneration Sales Value Share by Application (2021-2032)
6 Dry Age-Related Macular Degeneration Regional Value Analysis
  1. 6.1 Global Dry Age-Related Macular Degeneration Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dry Age-Related Macular Degeneration Sales Value by Region (2021-2032)
  3. 6.2.1 Global Dry Age-Related Macular Degeneration Sales Value by Region: 2021-2026
  4. 6.2.2 Global Dry Age-Related Macular Degeneration Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dry Age-Related Macular Degeneration Sales Value (2021-2032)
  7. 6.3.2 North America Dry Age-Related Macular Degeneration Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Dry Age-Related Macular Degeneration Sales Value (2021-2032)
  10. 6.4.2 Europe Dry Age-Related Macular Degeneration Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Dry Age-Related Macular Degeneration Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Dry Age-Related Macular Degeneration Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Dry Age-Related Macular Degeneration Sales Value (2021-2032)
  16. 6.6.2 South America Dry Age-Related Macular Degeneration Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Dry Age-Related Macular Degeneration Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Dry Age-Related Macular Degeneration Sales Value Share by Country, 2025 VS 2032
7 Dry Age-Related Macular Degeneration Country-level Value Analysis
  1. 7.1 Global Dry Age-Related Macular Degeneration Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dry Age-Related Macular Degeneration Sales Value by Country (2021-2032)
  3. 7.2.1 Global Dry Age-Related Macular Degeneration Sales Value by Country (2021-2026)
  4. 7.2.2 Global Dry Age-Related Macular Degeneration Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Dry Age-Related Macular Degeneration Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Dry Age-Related Macular Degeneration Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Dry Age-Related Macular Degeneration Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Santen Pharmaceuticals
  2. 8.1.1 Santen Pharmaceuticals Company Information
  3. 8.1.2 Santen Pharmaceuticals Business Overview
  4. 8.1.3 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
  6. 8.1.5 Santen Pharmaceuticals Recent Developments
  7. 8.2 Y2 Solution
  8. 8.2.1 Y2 Solution Company Information
  9. 8.2.2 Y2 Solution Business Overview
  10. 8.2.3 Y2 Solution Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Y2 Solution Dry Age-Related Macular Degeneration Product Portfolio
  12. 8.2.5 Y2 Solution Recent Developments
  13. 8.3 Stealth Biotherapeutics
  14. 8.3.1 Stealth Biotherapeutics Company Information
  15. 8.3.2 Stealth Biotherapeutics Business Overview
  16. 8.3.3 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product Portfolio
  18. 8.3.5 Stealth Biotherapeutics Recent Developments
  19. 8.4 Phio Pharmaceuticals
  20. 8.4.1 Phio Pharmaceuticals Company Information
  21. 8.4.2 Phio Pharmaceuticals Business Overview
  22. 8.4.3 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
  24. 8.4.5 Phio Pharmaceuticals Recent Developments
  25. 8.5 Ocumension Therapeutics
  26. 8.5.1 Ocumension Therapeutics Company Information
  27. 8.5.2 Ocumension Therapeutics Business Overview
  28. 8.5.3 Ocumension Therapeutics Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ocumension Therapeutics Dry Age-Related Macular Degeneration Product Portfolio
  30. 8.5.5 Ocumension Therapeutics Recent Developments
  31. 8.6 Kubota Vision
  32. 8.6.1 Kubota Vision Company Information
  33. 8.6.2 Kubota Vision Business Overview
  34. 8.6.3 Kubota Vision Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kubota Vision Dry Age-Related Macular Degeneration Product Portfolio
  36. 8.6.5 Kubota Vision Recent Developments
  37. 8.7 Iveric Bio
  38. 8.7.1 Iveric Bio Company Information
  39. 8.7.2 Iveric Bio Business Overview
  40. 8.7.3 Iveric Bio Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Iveric Bio Dry Age-Related Macular Degeneration Product Portfolio
  42. 8.7.5 Iveric Bio Recent Developments
  43. 8.8 Eyestem Research
  44. 8.8.1 Eyestem Research Company Information
  45. 8.8.2 Eyestem Research Business Overview
  46. 8.8.3 Eyestem Research Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eyestem Research Dry Age-Related Macular Degeneration Product Portfolio
  48. 8.8.5 Eyestem Research Recent Developments
  49. 8.9 Belite Bio
  50. 8.9.1 Belite Bio Company Information
  51. 8.9.2 Belite Bio Business Overview
  52. 8.9.3 Belite Bio Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Belite Bio Dry Age-Related Macular Degeneration Product Portfolio
  54. 8.9.5 Belite Bio Recent Developments
  55. 8.10 Bausch Health
  56. 8.10.1 Bausch Health Company Information
  57. 8.10.2 Bausch Health Business Overview
  58. 8.10.3 Bausch Health Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bausch Health Dry Age-Related Macular Degeneration Product Portfolio
  60. 8.10.5 Bausch Health Recent Developments
  61. 8.11 Allergan
  62. 8.11.1 Allergan Company Information
  63. 8.11.2 Allergan Business Overview
  64. 8.11.3 Allergan Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Allergan Dry Age-Related Macular Degeneration Product Portfolio
  66. 8.11.5 Allergan Recent Developments
  67. 8.12 Alimera Science
  68. 8.12.1 Alimera Science Company Information
  69. 8.12.2 Alimera Science Business Overview
  70. 8.12.3 Alimera Science Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Alimera Science Dry Age-Related Macular Degeneration Product Portfolio
  72. 8.12.5 Alimera Science Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst